# Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)

> **NCT02570542** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 59 (actual)

## Conditions studied

- Diffuse Large B-cell Lymphoma (DLBCL)
- Relapsed Diffuse Large B-cell Lymphoma (DLBCL)
- Refractory Diffuse Large B-cell Lymphoma (DLBCL)

## Interventions

- **PROCEDURE:** leukapheresis
- **DRUG:** Plerixafor
- **DRUG:** carmustine, etoposide, cytarabine, melphalan
- **PROCEDURE:** Autologous Stem Cell Transplantation

## Key facts

- **NCT ID:** NCT02570542
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-10
- **Primary completion:** 2026-10
- **Final completion:** 2026-10
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2025-11-26

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02570542

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02570542, "Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02570542. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*